Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

LMCC Returns October 20 & 21 To Hudson Yards: Presenting The World’s Top Cannabis & CBD Beauty, Wellness, Food & Beverage Brands

LMCC Ventures LLC

New York, NY, October 18, 2022 — Luxury Meets Cannabis Conference (LMCC) today announced the complete program for its Fall 2022 Edition, which returns on October 20 & 21 in Hudson Yards, New York City. Launched in 2018 as a first-of-its-kind B2B trade event, LMCC has grown into the go-to resource and venue for product discovery and extensive category education, connecting visionary CBD and Cannabis brands across the beauty/wellness, food/beverage, and technology/lifestyle accessory categories to mainstream retailer buyers, luxe dispensaries, media, and investors. As an indication of the excitement around the emerging New York legal Cannabis market and the official brand showcase mix at LMCC, 100+ A-tier retail outlets – LMCC’s highest rate to date – have registered to attend the show including KITH, Standard Dose, Curaleaf, Bloomingdale’s, Rise Cannabis, Etain, The Vitamin Shoppe, Shen Beauty, and many others. LMCC’s inaugural infused Food & Beverage Hall will also debut, which will feature the finest food/culinary, beverage, consumables, and confectionery brands in the space — especially timely as alcohol sales in the U.S. continue to decline. This Harrods-esque, immersive (and delectable) experience will spotlight leading brands such Cann, Kiva Confections, oHHo, Cycling Frog, Cloud 11, Black Dahlia, L8, Sass, Chef For Higher, and many more. More than 700 business attendees from around the world will explore the LMCC Official Brand Showcase — a pre-vetted, store-ready exhibition — paired with a full schedule of keynote talks, brand presentations, and business networking. For the most up-to-date information on partners, exhibiting brands and speakers, visit lmccshow.com. LMCC FALL 2022 OFFICIAL BRAND SHOWCASE DIRECTORY Astraèa & Co. Black Dahlia CANDOR CANN Chef for Higher Cloud 11 Cycling Frog Daily Habit Drew Martin errbshop Franny’s Farmacy Function Botanicals The Healing Rose Hudson Cannabis Innocan Pharma K’dara Kiva L8 LEUNE LumiBloom MĀSK Skincare oHHo Plantwise REUNION Sackville & Co. SASS StellaVia Stone Road UB Super / Meticulous Skincare WALALA LMCC SPEAKER SCHEDULE NOW LIVE See 50 leading executives on stage from Ulta Beauty, Adweek, New York State Cannabis Control Board, Merida Capital Holdings, Adweek, Different Leaf, NYC Mayor’s Office, Food & Wine, Standard Dose, Women’s Health, and Bon Appétit and many others: View LMCC Fall 2022 Speaker Schedule Here ### Attendee Tickets: Two-day, all-access passes to LMCC 2022 are $695. Purchase passes HERE. Retail Buyer Registration: Admission is complimentary only for qualified retail buyers and their teams. Stores, dispensaries, and e-tailers only can register HERE. Sponsors: LMCC is proud to partner with Merida Capital Holdings Brand Applications: Now Accepting Submission for LMCC May 2023 Brands Can Now Reserve Space for LMCC 2023 Here About LMCC: Founded in 2018, LMCC Ventures LLC is the parent company of the annual Luxury Meets Cannabis* Conference (LMCC) in New York City. LMCC is the premier B2B event connecting A-tier retailers, media, investors, leading dispensaries and CPG executives to premium CBD, hemp and Cannabis brands — with a keen focus on beauty, wellness, food & beverage. Past participants include retailers like Sephora, Nordstrom, Credo Beauty, and Bloomingdale’s; media including The New York Times, Glossy, Travel & Leisure, O, The Oprah Magazine, and Robb Report; and speakers from Mitch Baruchowitz (Merida Capital Holdings) and Cindy Capobianco (Lord Jones) to Bobbi Brown and Frederic Fekkai. For more information on LMCC, visit lmccshow.com. Find LMCC socially on LinkedIn and Instagram. Guidelines & Legal: no smoking or vaping on any kind permitted inside the venue. Local laws strictly apply. Contact Details Katie Shapiro +1 303-882-5596 katie@katieshapiromedia.com Company Website https://www.lmccshow.com/

October 19, 2022 09:00 AM Eastern Daylight Time

Chill Brands kicks off "new era" with website relaunch

Chill Brands Group PLC

Contact Details Proactive Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 19, 2022 06:51 AM Eastern Daylight Time

Video

Are You Paying Too Much for Your Medicare Plan?

YourUpdateTV

October 15 marked the start of the Medicare Annual Enrollment Period — a time for Medicare-eligible people to choose the plan that best supports their unique needs and budget. Recently, Vice President of Aetna Medicare Bob O’Connor, participated in a nationwide satellite media tour to discuss what you need to know for thisAnnual Enrollment Period. A video accompanying this announcement is available at: https://youtu.be/jriqOx0-9pc With the national inflation rate at an all-time high since the 1980s, it’s more important than ever for older adults, who are often on a fixed income, to evaluate their individual health care needs and choose a Medicare plan that best supports those needs in a cost-effective way. The 2022 Health Care Insights Study by CVS Health found that 90 percent of providers said cost of care is a top concern for their 65-and-older patients. Medicare can be confusing because there are a lot of different options out there. And if you’re around Medicare age, your mailbox will soon be flooded with Medicare plan letters, postcards and ads. Think about what’s important to you and ask yourself some basic questions, like does the plan fit your budget and does your plan cover your doctors, hospitals, and pharmacies? Another important thing to consider is prescription drugs. Are there prescription drugs you take regularly? Does the plan’s drug list cover those prescriptions? It’s also important to know what tier your prescription drugs are on or whether there are any coverage rules. The first thing people should do is go to the Medicare.gov website. Once there, they can enter their zip code and see all the Medicare plans available in their area. And of course, you can learn more about 2023 Aetna Medicare plans at AetnaMedicare.com or call us at 1-844-588-0041 (TTY: 711), 7 days a week, 8 AM to 8 PM. The Medicare Annual Enrollment Period runs from October 15 through December 7, 2022. A licensed agent may answer your call. About Bob O’Connor As Vice President of Aetna Medicare and community volunteer for organizations focused on seniors and the disabled, Bob O’Connor brings a unique perspective to the Medicare conversation. He’s worked in several roles at Aetna in support of seniors and currently oversees member experience, quality and business strategy for Aetna’s robust portfolio of Medicare Advantage plans. An advocate for the aging population, Bob is passionate about improving health care and helping Aetna’s more than 10.6 million Medicare members nationwide achieve their best health. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

October 18, 2022 12:37 PM Eastern Daylight Time

Video

Jupiter Wellness’s Potential New OTC Drug Could Put Some More Joy Back Into Breast Cancer Survivors’ Lives

Jupiter Wellness, Inc.

Learn More about Jupiter Wellness Inc. by gaining access to the latest research report Breast cancer has surpassed lung cancer as the most commonly diagnosed cancer globally as of 2021, according to the American Cancer Society and the International Agency for Research on Cancer. Although breast cancer is one of the more talked-about cancers, there are many disturbing facts related to this deadly disease that make it more alarming than other cancers. Stats Show Breast Cancer Continues To Wreak Havoc On Women’s Lives Here are some of the latest stats: About 1 in 8 U.S. women (about 13%) will develop invasive breast cancer over the course of their lifetimes. As of January 2022, there are more than 3.8 million women with a history of breast cancer in the U.S., including women currently being treated and women who have finished treatment. In 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S. Breast cancer affects men, too, and about 2,710 new cases of invasive breast cancer are expected to be diagnosed in men in 2022 with a man’s lifetime risk of breast cancer being about 1 in 833. About 43,250 women in the U.S. are expected to die of breast cancer in 2022. Death rates have been steady in women under 50 since 2007 but have continued to drop in women over 50 because of screening and early detection and care. About 85% of breast cancers occur in women who have no family history of breast cancer. These occur because of genetic mutations that happen as a result of the aging process and lifestyle — less than 15% of women who get breast cancer have a family member diagnosed with it. Several pharmaceutical companies including Bristol-Myers Squibb Co. (NYSE: BMY), Merck & Co. Inc. (NYSE: MRK), Medivation Inc. (NASDAQ: MDVN), and Pfizer Inc. (NYSE: PFE) have reported developing breakthrough drugs to treat breast cancer over the years. And considerable progress has been made in reducing cancer rates and improving cancer survival through improved diagnostic and treatment modalities, according to reports. Yet the adverse effects of cancer treatment continue to cause concern and unhappiness for breast cancer survivors. Following breast cancer treatment or surgery, some women experience a number of side effects, including a change in body weight, tightness of the skin, changes in sensation, phantom breast sensations (in surgery patients), and loss of sexual desire (libido). The sexual health of women and female libido have always been awkward topics of conversation that are seldom discussed openly. Women don’t want to talk about it and it seems little attention has been paid to developing drugs catering to female sexual wellness. And, by extension, their male partners. A Side Effect That Could Regenerate Libido? Spark Joy? But one Florida-based BioPharma company has licensed a breakthrough product with a novel mechanism of action for women’s sexual wellness. As per a recent press release, “The exclusive license includes issued patents and technology, including formulations. In clinical studies, one topical formulation improved nipple sensitivity and alleviated associated sexual problems. Concomitantly, the formulation was also shown to increase female sexual lubrication and improve overall orgasmic response.” Jupiter Wellness Inc. (NASDAQ: JUPW) reports that its proposed drug, JW-500, when topically applied to the nipple-areola area of the breast, contracts the smooth muscle, thus erecting the nipple and increasing its sensitivity. The company reports that clinical trials of JW-500 have shown efficacy and safety in improving female nipple sensitivity. Further testing is being conducted to quantify and qualify enhanced sexual arousal, vaginal lubrication, and orgasm response in healthy women and women suffering from nipple naturopathy following breast cancer treatment. "This treatment has the potential to address a wide range of clinical indications, including nipple neuropathies following breast augmentation in breast cancer survivors”, said Jupiter Wellness CEO Brian John."We are excited to complete the research and development of this product and to bring this novel approach to the market. I believe this product may not only be an excellent treatment for people with breast cancer but potentially as a women's sexual health product as well." The company plans to file for a pre-IND meeting with the US FDA within the next 12 months and intends to seek Orphan Drug Designation for JW-500. Considering the size of the market for breast cancer survivors and the possibility of addressing libido loss in post-menopausal women, Jupiter Wellness may be a company to keep an eye out for news on their clinical progress. To learn more about JW-500 and Jupiter Wellness, visit its webpage. We support health and wellness through the research and development of over-the-counter (OTC) products and intellectual property. Our product pipeline addresses a range of conditions, including hair loss, eczema, burns, and sexual wellness. Revenue is generated through the sales of OTC and consumer products, contract research agreements, and licensing royalties. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR- Camille Baptiste camille@tradigitalir.com Company Website https://jupiterwellness.com/

October 18, 2022 09:09 AM Eastern Daylight Time

Ready for Ron Announces National Student Director

Ready for Ron

Ready for Ron, the only credible independent group working to Draft Florida Governor Ron DeSantis to run for President, announced a new initiative to engage college students, as activists and volunteers, in support of the official national petition to draft Ron DeSantis to run in 2024. ‘Young Americans Ready for Ron’ led by Dylan Dean, will build a nationwide network of student activists to actively engage their fellow students and their local communities as part of the growing national movement in support of a Presidential run by Governor DeSantis. Dean, a student at Montana State University served as a multi-State Chair for the renowned student activist movement Young Americans for Liberty (running five states at once) and is a tireless advocate on and off college campuses. Dean’s experience in grassroots organizing and action has helped him build a national network of Young Americans ready to engage in electoral activism. “My generation is Ready for Ron to continue defending freedom and liberty - just as he has done in Florida – but on the national stage. Since the onset of the COVID-19 pandemic, Governor DeSantis refused to kowtow to the radical Left, keeping the Sunshine State open for business and rejecting the impulse to impose onerous mask and vaccine mandates on citizens of the state. It revealed true bravery and respect for liberty, and that's why I support him now," Dylan Dean said. “By choosing guidelines over mandates, Governor DeSantis has given hope to college students like myself, who can now look to 2024 with newfound optimism that he will win the White House,” Dean continued. For those still in the college system or who just left it, we know what a broken system looks like and how important it is to solve the problems. Only strong leadership can get that job done.” “We are thrilled to have Dylan involved with this effort,” stated Ready for Ron Chief Political Strategist Ed Rollins. We need more younger people involved to grow a powerful apparatus nationwide to draft and elect Ron DeSantis for President. Their future and ours depend on it.” Since its launch in late May, Ready for Ron has enlisted nearly one hundred thousand supporters, generated significant media attention, and run hundreds of ads to convince Ron DeSantis to run for President. Ready for Ron has emerged as the only credible independent organization in support of a Ron DeSantis candidacy. Americans are encouraged to sign the petition at ReadyForRon.com to draft Ron DeSantis to run in 2024. ### Contact Details Dan Rene +1 202-329-8357 dan@readyforron.com Company Website https://www.readyforron.com/

October 18, 2022 08:45 AM Eastern Daylight Time

Precision Medicine Could Get Even More Precise With Allarity Therapeutics’ “Next-Generation” Diagnostics Platform

Allarity Therapeutics, Inc.

Once brought into its pipeline, Allarity uses its DRP® platform to develop companion diagnostics alongside each drug to improve the treatments in a personalized medicine approach. Earlier this year, the company refocused its pipeline strategy toward combination therapies in an effort to improve treatment outcomes while also creating more funding and partnership opportunities. Allarity Therapeutics Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on oncology treatments. After decades of research, the company has created what it describes as a powerful next-generation companion diagnostics platform, called Drug Response Predictor (DRP®), and is now developing a portfolio of promising cancer treatments. Companion Diagnostics Are Helping Doctors Deliver The Right Cancer Treatment To The Right Patient At The Right Time Companion diagnostic tests help doctors quickly and accurately identify which treatments a particular person is most likely to respond to so that they can develop a personalized treatment plan that has the highest odds of being successful for that cancer patient. Earlier versions of these tests would look at a single gene or a small handful of genes known to be predictors of treatment response. This can provide a limited view of the patient’s potential response. Take, for example, the epidermal growth factor receptor (EGFR) expressed in some colorectal cancers. A test identifying this biomarker might identify the patient as a candidate for anti-EGFR therapy. However, tumors with EGFR alongside KRAS or NRAS mutations are often resistant to anti-EGFR therapy. But if the test isn’t looking at that biomarker of resistance, it could misidentify them as a candidate for the therapy when they really aren’t. To account for those limitations, the next generation of diagnostic tests is broadening the scope. Foundation Medicine Inc.’s FoundationFocus CDx, for example, was the first companion diagnostic assay approved by the Food and Drug Administration (FDA). It analyzes 324 genes to predict responsiveness to treatments for five types of cancer. Similarly, Myriad Genetics Inc. (NASDAQ: MYGN) launched its new Precise Tumor test earlier this year that analyzes over 500 tumor-related genes. However, these are still constrained by the limits of the biomarkers science has identified so far. That means biomarkers of resistance or responsiveness that researchers don’t know about yet could impact the accuracy of the results. Allarity’s Proprietary Drug Response Predictor Platform Reported To Deliver Even More Precision Allarity’s Drug Response Predictor (DRP®) platform is a unique bioanalytical platform that can create drug-specific predictive diagnostics for a wide range of cancer treatments. Unlike other companion diagnostics on the market, Allarity’s DRP® looks at the entire 25,000-plus genes expressed in a cancer cell — not just the ones science has already identified as biomarkers of responsiveness. Over the past two decades, the company has developed this platform through dozens of clinical trials and the analysis of thousands of human tumor biopsy samples to create the robust platform. The result is a platform that can bridge the gap between how cancer cells respond to a given drug in vitro versus how actual patient tumors respond. It can then create drug-specific biomarker signatures, a set of 50 to 400 genes that predict how a patient’s cancer is likely to respond to a specific treatment. A DRP® companion diagnostic delivers its results in the form of a score on a color-coded spectrum where green means the patient is a high match, likely to respond to a drug, and red means the patient is unlikely to respond because they have too many genes predicting resistance to that treatment. In other words, the DRP® not only identifies likely candidates for a drug but also rules out unlikely responders so doctors can more effectively narrow in on the best treatment options for each patient. This precision has yielded promising results in clinical trials. Across the dozens of clinical trials done to develop this platform, DRP® has shown it offers twofold to fivefold improvements in overall response rate or time to progression compared to patients not selected with the DRP® companion diagnostic. The DRP® platform has been extensively published in peer-reviewed scientific journals and is patented. This genome-wide scope covering all 25,000-plus cancer genes gives Allarity the ability to develop a companion diagnostic for every drug it brings into its pipeline as well as partner with other companies to develop tests for the drugs in their pipelines. A Low-Risk Pipeline Of Promising Oncology Drug Candidates? The Massachusetts-based pharmaceutical has minimized the risks associated with drug development by only having acquired drug candidates from other companies, including big pharma, that have already demonstrated safety and efficacy in early trials. Most of Allarity’s pipeline programs are former big pharma assets that have progressed past Phase 1 studies or later Phase 2/3 studies. Stenoparib, for example, is being evaluated as a treatment for ovarian cancer. Allarity licensed it from Eisai Co. Ltd. (OTCMKTS: ESALY). It now planning to evaluate stenoparib in combination with dovitinib, a drug candidate with multiple indications that Allarity licensed from Novartis AG (NYSE: NVS). Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRPÂ® platform. The Company has a mature portfolio of five drug candidates: stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer; dovitinib, a post-Phase 3 pan-tyrosine kinase inhibitor; IXEMPRAÂ® (Ixabepilone), a microtubule inhibitor approved in the U.S. for the treatment of second-line metastatic breast cancer and in Phase 2 development in Europe for the same indication; and 2X-111, a liposomal formulation of doxorubicin in Phase 2 development for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject of discussions for a restructured out-license to Smerud Medical Research International AS. LiPlaCisÂ®, a liposomal formulation of cisplatin and its accompanying DRPÂ® is being developed via a partnership with Chosa ApS, an affiliate of Smerud Medical Research International, for late-stage metastatic breast cancer. The Company is headquartered in the United States and maintains an R&D facility in Hoersholm, Denmark. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Thomas Pedersen tsp@carrotize.com Company Website https://allarity.com/

October 18, 2022 08:00 AM Eastern Daylight Time

Halloween Thrills Can Be Good for Your Mental Health & Reduce Stress of Daily Living

The Chicago School of Professional Psychology

During a time when many of us are anxious about daily living, the thrill of a Halloween fright might alleviate some stress, according to Dr. Michele Nealon, Psy. D., President of The Chicago School of Professional Psychology. “There’s a psychological release from knowing that we can overcome our fear and enjoy the feeling of being exposed to crisis or threat in a safe environment,” she said. “This could be exactly the kind of release we need from our daily stresses—even if it’s just for a few moments.” “When you visit a haunted house or watch a horror movie, there’s a rush of adrenaline, endorphins and dopamine,” Dr. Nealon added. “This rush is translated by our brain into feelings of euphoria, satisfaction and empowerment when the fear subsides. We get a sense of relief and well-being.” Thrill seekers who test their own limits can also reinforce bonds with others when this experience is shared, according to Dr. Nealon. But there is a downside to Halloween that Dr. Nealon warns about. “When we mock the disadvantaged, the mentally ill, those with special needs, or anyone with a perceived difference, we contribute to stigma and discrimination which makes it even tougher for people living with adversity. This Halloween, and always, be mindful that there are those around you who are struggling—they need your support, your kindness, and not your taunts.” “Today, we have enough real fear and anxiety in our daily lives. Halloween frights can be an appropriate way to release some of the pent-up tension in our bodies so that we can better tackle the actual challenges we face,” she said. “At the same time, it’s a time to reflect on how we, as a society, need to focus on how to better serve those most in need of our support and kindness, understanding that this is an important step to community wellness for all of us,” Dr. Nealon said. Contact Details The Chicago School of Professional Psychology Vivien Hao, Public Relations Manager +1 323-893-4743 vhao@thechicagoschool.edu

October 17, 2022 01:00 PM Pacific Daylight Time

Fall Finds!

News Media Group, Inc.

Contact Details News Media Group, Inc. Karl Wayne +1 334-440-6397 karl@newsmg.com Company Website https://newsmg.com/

October 17, 2022 11:01 AM Eastern Daylight Time

Video

AmeriLife and AIMCOR Group Launch New Venture to Expand Best-in-Class Distribution Model

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions, announced today that it has entered into a joint venture with AIMCOR Group LLC (“AIMCOR”) to launch AIMCOR Consolidated, LLC (d/b/a ICON). Per the agreement, terms of the deal were not disclosed. ICON will focus on creating strategic partnerships under a centralized infrastructure with access to AmeriLife’s best-in-class shared services, diverse product portfolio, and vast, proprietary distribution opportunities. Additionally, ICON will provide AmeriLife access to a fully underwritten life platform that will further expand the company’s offerings and help deliver on a growing strategic priority. “As we continue to invest in our industry-leading distribution, it’s important that we find creative ways – and the right partners – to help accelerate and sustain our growth ambitions,” said Scott R. Perry, chairman and CEO of AmeriLife. “We’re excited to join forces with AIMCOR in this venture and, together, deliver on our shared legacies of excellence and business transformation for member companies.” “The launch of ICON is not only a big moment for AmeriLife and AIMCOR, but a big win for the distribution industry,” added Mike Vietri, Chief Distribution Officer for AmeriLife. “Our unique collaboration will fuel the success of a new generation of companies by fortifying a platform of holistic health, life and retirement solutions that their agents and advisors will never outgrow – and ensuring their clients never outgrow them.” "During the last decade, AIMCOR has had a clear and steadfast vision about how it wanted to expand and evolve its business model,” said John C. Ziambras, president and CEO of AIMCOR Group. “Our partnership with AmeriLife not only enables us to execute on one of our core strategic objectives of facilitating succession planning and business continuation, but also adds a unique differentiator to our value proposition by bringing significant top- and bottom-line growth opportunities to our member firms.” Marc R. Verbos, executive vice president for AIMCOR Group, will serve as president of ICON and manage the day-to-day operations of the new entity. Added Verbos: “The creation of ICON, under our aligned distribution channel, allows us to take AIMCOR’s three core drivers – organic growth, distribution expansion and business transformation – to the next level by adding access to AmeriLife’s investment capital, ancillary product lines and expanded distribution opportunities, all in a shared ownership structure that will greatly benefit existing and future members and the broader industry.” ### About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. About AIMCOR Group AIMCOR Group is a National Insurance Marketing Organization that distributes and services life, disability, LTC and annuity products through a variety of channels and platforms. Since its inception in 2011, and in conjunction with its internal and external partners, AIMCOR has embarked on a shared vision of industry business transformation by enabling new distribution, engaging consumers and delivering financial security to American families across all ages, income levels and cultural backgrounds. For more information, visit aimcorgroup.com, and follow AIMCOR on LinkedIn. Contact Details AmeriLife Media Relations Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com AIMCOR Group Mike English +1 866-428-0180 mike.english@aimcorgroup.com AmeriLife Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

October 17, 2022 09:07 AM Eastern Daylight Time

1 ... 201 202 203 204 205 ... 310